About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
KU ASCO 2019 Long-Term Survival of Dabrafenib Plus Trametinib in Metastic BRAF-Mutated Melanoma & PR and Survival of Neoadjuvant Therapy
By
KU Hematology & Medical Oncology Review 2019
FEATURING
Gary Doolittle
By
KU Hematology & Medical Oncology Review 2019
FEATURING
Gary Doolittle
233 views
August 22, 2019
0 Comments
Login to view comments.
Click here to Login
Related Content
AUTOPLAY
ON
13:47
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Expanding the Benefit - Dabrafenib/Tramet…
Feat.
V. Subbiah
23:09
Total Health
Key Updates in Skin Melanoma
Feat.
R. Seedor
06:39
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Final Analysis of Distant Metastasis-Free…
Feat.
J. Luke
17:50
AdventHealth
Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…
Feat.
G. Sonpavde
24:14
Masterclasses in Dermatology
Advances in the Treatment of Melanoma
Feat.
D. Fisher
17:39
Melanoma Bridge 2023
Major Emerging Paradigm Shifts That Will Change Melanoma Management …
Feat.
A. Eggermont
05:20
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Impact of Immune Checkpoint Inhibition on…
Feat.
E. Buchbinder
08:38
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "A Phase 3 Trial Comparing Fianlimab + Cem…
Feat.
T. Panella
19:52
OncoAlert
Melanoma Updates: Adjuvant Therapy, Advanced Disease, Uveal Melanoma…
Feat.
A. Betof Warner
21:04
Penn Medicine Abramson Cancer Center
Pediatric Melanoma
Feat.
M. Jen
05:37
Melanoma Bridge 2023
COLUMBUS 7-Year Update: Encorafenib + Binimetinib vs. Vemurafenib or…
Feat.
R. Dummer
08:46
Sapna Patel
Neoadjuvant Immunotherapy in the Treatment of Melanoma: What Do We K…
13:12
2023 Year in Review
Year in Review: Surgical Treatment of Acral Melanoma
Feat.
M. Leventer
14:00
Melanoma Bridge 2023
Is SLN Biopsy No Longer Necessary for Patients With High-Risk Primar…
Feat.
J. Luke
10:39
University of Colorado Department of Medicine
Cardio-Oncology: Definitions and Scope
Feat.
L. Kondapalli
08:27
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Significant Durable Response With Fianlim…
Feat.
O. Hamid
25:10
Scripps MD Anderson Cancer Center Clinical Hematology & Oncology 2024
Immunotherapy Combinations in Melanoma in 2024
Feat.
J. Moyers
04:45
Sapna Patel
Optimal Duration of Neoadjuvant Treatment in Melanoma: What We Do No…
17:38
Melanoma 2024: 34th Annual Cutaneous Malignancy Update
Beyond the Primary: Comprehensive Evaluation of the Melanoma Patient…
Feat.
F. Fish
02:49
GRACE
Major Advances in Uveal Melanoma
Feat.
M. Postow
